METHODS: This retrospective analysis identified adult, female breast cancer patients who initiated trastuzumab treatment (index date) from a large U.S. claims database. Inclusion criteria also required ≥ 2 claims for both trastuzumab (from July 1, 2006, to July 31, 2012) and breast cancer (during 6-month pre-index baseline period), no evidence of metastatic breast cancer or other cancers in the baseline period, and continuous enrollment with commercial or Medicare Advantage coverage 6 months pre-and post-index, except that patients who died during follow-up were retained. Patients with evidence of trastuzumab receipt during the baseline period or more than 1 site of care during follow-up were excluded. Patients were stratified by site of care and were followed from index date to 30 days after the last trastuzumab infusion prior to a gap ≥ 90 days, death, disenrollment, or end-of-study period. Differences in treatment patterns between the POV and HOP cohorts were assessed by t-test and chi-square test. The relationship between site of care and health care costs was modeled with a generalized linear model with gamma distribution and log link, and the number of trastuzumab infusions was modeled with negative binomial regression controlling for log follow-up time. All models were adjusted for age, baseline comorbidity score, and insurance type.
RESULTS: Of the 3,439 breast cancer patients identified, 77.6% (2, 669) received adjuvant trastuzumab in the POV setting. Mean age (53.7 years) and baseline comorbidity score (3.91) were similar among cohorts; a higher percentage of POV versus HOP patients had commercial insurance (91.1% vs. 86.4%, P < 0.001). Compared with the POV cohort, HOP patients had a shorter mean duration of trastuzumab treatment (324.8 vs. 343.0 days, P < 0.001); more treatment gaps (30-59 day gap: 67.4% vs. 24.1%, P < 0.001); and fewer trastuzumab infusions per month (1.37 vs. 1.98, P < 0.001) during follow-up. In multivariate analysis, the monthly count of trastuzumab infusions in the HOP cohort was lower than the POV cohort (incidence rate ratio = 0.693; 95% CI = 0.672-0.715). Adjusted per patient per month total health care costs were 53.6 % higher in the HOP setting (cost ratio = 1.536, 95% CI = 1.472-1.604).
CONCLUSIONS: Breast cancer patients treated with adjuvant trastuzumab in the HOP setting had a shorter duration of trastuzumab treatment and fewer trastuzumab infusions but incurred higher monthly total costs than patients treated in the POV setting.
• Breast cancer is the most common cancer among women in the United States and globally. Treatment of early stage breast cancer commonly includes adjuvant chemotherapy.
• Chemotherapy is typically administered in a hospital outpatient or physician office setting.
• Reports in the nonpeer-reviewed literature suggest that the cost of cancer care is higher in the hospital outpatient setting than the physician office setting.
What is already known about this subject
• This study focuses on adjuvant treatment of breast cancer with trastuzumab. We examined the impact of site of care on duration and frequency of trastuzumab treatment and health care costs.
• Compared with patients treated in the physician office setting, patients treated in the hospital outpatient setting had a shorter mean duration of trastuzumab treatment and fewer mean monthly counts of trastuzumab infusions.
• Despite fewer monthly trastuzumab infusions, total monthly health care costs of patients treated in the hospital outpatient setting were 53.6% higher, and costs per infusion day were 2.7 times higher than patients treated in physician office settings. Outpatient pharmacy claims provide National Drug Codes (NDC) for dispensed medications, quantity dispensed, drug strength, and number of days of supply. Patients who died during the study were identified, and date of death was estimated based on a combination of hospital discharge status from medical claims and month and year of death using data from the Social Security Administration master death file. All study data were accessed using protocols compliant with the Health Insurance Portability and Accountability Act of 1996, and no identifiable protected health information was extracted during the course of the study. Thus, institutional review board approval was not sought.
■■

Study Subject Identification
Patients were considered for inclusion if they had at least 2 medical claims indicating receipt of trastuzumab (HCPCS code J9355) between January 1, 2006, and July 31, 2012. The index date was the date of the first claim for trastuzumab during this period, and the baseline period was the 6-month period prior to the index date. Patients were required to have no evidence of receipt of trastuzumab during the baseline period. Additional inclusion criteria were the following: (a) ≥ 2 claims with a diagnosis of female breast cancer (ICD-9-CM 174.xx), at least 30 days apart during the baseline period (starting as early as July 1, 2005) and end of health plan enrollment (as late as July 31, 2012); (b) ≥ 18 years old; (c) continuous enrollment in a commercial or Medicare Advantage plan with a medical and a pharmacy benefit during the 6-month baseline and for at least 6 months after the index date (follow-up period). Patients with less than 6 months of follow-up time due to death were included. Data from the Social Security Administration master death file were used to distinguish between death and disenrollment due to reasons other than death.
Patients were required to have no evidence of receipt of trastuzumab at multiple sites of service. Patients were excluded is typically administered in a hospital outpatient clinic or, more commonly, a physician office. Under the 340B program, eligible hospital outpatient clinics may receive 20%-50% discounts on chemotherapy drug acquisition costs, and the number of hospitals participating in 340B programs nearly tripled between 2005 and 2011. 8 However, these drug discounts are typically not available to community-based oncology clinics. Since 2005, the contribution of net drug revenue to total net revenue has declined sharply in community practices. 9 Surveys suggest that more of these practices are closing, being acquired by larger entities (i.e., hospitals or universities), 10 or referring patients to hospital outpatient clinics. 11 A shift in the site of chemotherapy administration from physician offices to hospital outpatient sites warrants investigation to understand the cost implications.
12
Three nonpeer-reviewed studies indicate that the cost of cancer care for patients receiving chemotherapy in hospital outpatient settings is more expensive than for patients receiving chemotherapy in physician office settings. [13] [14] [15] Compared with the physician office setting, commercially insured patients incurred 20% to 80% higher costs per chemotherapy episode, 13 and Medicare fee-for-service patients had 14% higher annual costs in hospital outpatient settings.
14 While these studies provide an important overview of differences in costs by site of care, they do not account for potentially confounding factors such as the presence of other cancers, metastatic disease, and treatment regimen. A third analysis, which stratified patients by 3 cancer types and adjuvant versus metastatic treatment, identified higher costs in the hospital outpatient setting; for adjuvant treatment of breast cancer by any chemotherapy regimen, costs per chemotherapy episode were 50% higher in the hospital outpatient setting. 15 Chemotherapy regimens approved for adjuvant treatment of breast cancer may also include targeted agents. Our goal was to further explore potential differences by site of service by focusing on adjuvant treatment of early stage breast cancer with trastuzumab, a clinical setting where treatment regimen confounders can be minimized. Trastuzumab is a humanized IgG1 monoclonal antibody that inhibits the proliferation of tumor cells that overexpress human epidermal growth factor receptor (HER-2). 16 Overamplification of HER-2 is observed in approximately 20%-25% of breast cancers, 17 and in the adjuvant setting, trastuzumab is indicated for treatment in combination with certain chemotherapy regimens or as a single agent following multimodality anthracycline-based therapy. The objective of this study was to investigate the impact of site of care on trastuzumab-treatment patterns, including frequency of infusions and duration of therapy, in breast cancer patients receiving adjuvant trastuzumab therapy. We also assessed health care utilization and costs in the 2 settings.
if they had more than 1 type of primary cancer (ICD-9-CM 140.xx-172.xx, 175.xx-195.xx, 199.xx-209.xx) in addition to breast cancer during the study period (July 31, 2005-July 31, 2012); patients were defined as having more than 1 cancer type if they had at least 2 claims of the same cancer type (based on 3-digit ICD-9-CM codes) at least 30 days apart. Patients with evidence of other primary cancers, pediatric patients, and those with missing cost data were excluded. Also excluded were male patients with breast cancer and female breast cancer patients with metastasis (ICD-9-CM 196.xx-198.xx, in any position) as evidenced by ≥ 2 claims at last 30 days apart during the baseline period and up until 30 days post-index.
Cohort and Treatment Period Identification
Patients were assigned to 1 of 2 cohorts based on the location where they received treatment (site of service) during the follow-up period. Patients who received trastuzumab exclusively in a hospital outpatient (HOP) setting were assigned to the HOP cohort, and patients who received trastuzumab exclusively in a physician office (POV) setting were assigned to the POV cohort. Patients who received treatment in both the hospital outpatient and physician office settings were excluded (if the patient changed doctors during treatment but the site of the service remained the same, the patient was retained). Follow-up treatment periods were identified for each patient as an episode of care (EOC) for the purpose of analysis. An EOC began on the date of the first trastuzumab infusion (index date) and ended at the earliest of (a) 30 days after the last drug administration that occurred prior to a gap of at least 90 days in trastuzumab therapy; (b) death; (c) health plan disenrollment; or (d) the end-of-study period (July 31, 2012). It was possible for an EOC period to involve more than 1 line of therapy. The outcomes for this study were assessed during the first EOC period.
Study Measures
Demographic and Clinical Characteristics. Patient demographics were examined as of the index date and included age, gender, insurance type, and geographic region in the United States (Northeast, Midwest, South, West). The baseline Charlson comorbidity score 18 was calculated for each patient based on the presence of diagnosis codes on medical claims during the baseline period. Evidence of cancer-related surgery, radiation, and hormone therapy was identified during the follow-up period.
Outcomes. Outcomes in the first EOC period during the follow-up included treatment patterns (evidence of combination chemotherapy, EOC length, count of trastuzumab infusions, gaps in trastuzumab administration); health care resource utilization (office visits, outpatient visits, emergency room [ER] visits, inpatient admissions, and length of inpatient stay); and monthly health care costs. Patients were considered to have evidence of combination chemotherapy if they received anticancer systemic therapy within 7 days (before or after) of the index date. The event rate for each resource utilization was computed as the total count of events per cohort divided by the total observation time of the cohort during the first EOC. The incident rate for ER and inpatient use was calculated as the number of patients who experienced the event divided by the observed time at risk. Thus, for incident rate, the number of patients who experience the event is included in the numerator, while the time at risk for experiencing the event is the denominator; patients who experience the event contribute to time at risk up until the event occurs, while patients who do not experience the event contribute the entire time observed during the study. Total health care costs represent the sum of reimbursed costs (health plan and patient-paid amounts after claims adjudication) for medical (office, outpatient, ER, inpatient, and other costs) and pharmacy costs. Cancer-related costs were computed from the sum of all medical and pharmacy costs with a diagnosis code for cancer in the primary or secondary position (ICD-9-CM 140.xx-172.xx, 174.xx, 175.xx-195.xx, 199.xx-209.xx). Costs were calculated per patient per month (PPPM). Two definitions of cost per infusion day were used: the broad definition was the sum of all costs that occurred on the infusion day, and the narrow definition was the aggregate costs of trastuzumab and trastuzumab infusion. All costs were adjusted to 2012 U.S. dollars based on the Consumer Price Index medical care component. 19 
Statistical Methods
Descriptive statistics were calculated for baseline demographic and clinical characteristics. Differences between cohorts in baseline characteristics, treatment patterns during EOC, and health care costs during EOC were analyzed by t-test (continuous variables) or chi-square test (dichotomous and polychotomous variables). Univariate analyses of cohort differences during the first EOC were conducted with the exact binomial test for health care utilization event and incident rates and t-test for differences in length of inpatient stay. Total monthly health care costs and the number of trastuzumab infusions per EOC were also examined by multivariate analysis. For costs, the model was constructed using a generalized linear model with gamma distribution and log link, and the appropriateness of the distribution was confirmed using a modified Park test. The count of trastuzumab infusions was modeled with negative binomial regression controlling for follow-up time. The dispersion factor of the count model was tested for the appropriateness of the negative binomial over a Poisson distribution. All models were adjusted for age, baseline Charlson comorbidity score, and insurance type (commercial or Medicare Advantage).
■■ Results Study Sample and Baseline Characteristics
A total of 9,722 patients had a claim for trastuzumab during the identification period and had no claims for trastuzumab during the baseline period (Figure 1 ). After applying all inclusion and exclusion criteria, 3,439 patients remained with 2,669 (77.6%) patients receiving treatment in the POV setting and 770 (22.4%) patients receiving treatment in the HOP setting. The baseline patient demographics and clinical characteristics are in Table 1 . Mean age (53.7 years) and Charlson comorbidity score (3.91) were similar among cohorts. Most patients had commercial insurance (90.0%), but a slightly higher proportion of patients treated in the POV setting had commercial insurance compared with the HOP setting (91.1% vs. 86.4%, P < 0.001).
Most patients received treatment in the South (49.7%) and Midwest (26.5%) census regions. Compared with the HOP cohort, a higher proportion of POV patients were treated in the South and West, and a lesser proportion were treated in the Northeast and Midwest. The percentage of patients receiving maintenance chemotherapy and/or radiotherapy was similar between cohorts. The most common reason for the end of the first EOC was a ≥ 90-day gap in trastuzumab administrations (1, 916 Table 2 , and the multivariate analysis for the number of trastuzumab infusions per EOC is in Table 3 . The mean duration of the first EOC was shorter in the HOP than in the POV setting (324.8 days vs. 343.0 days, P < 0.001). The proportion of patients with evidence of combination therapy was the same (84.6%) in both cohorts. Compared with the POV setting, there were fewer mean trastuzumab infusions in HOP for the entire EOC (14.6 vs. 22.3, P < 0.001) and per month (1.4 vs. 2.0, P < 0.001). A greater percentage of patients receiving treatment in the HOP setting had gaps in trastuzumab administration of 30-59 days (67.4% vs. 24.1%, P < 0.001) and 60-89 days (13.3% vs. 5.1%, P < 0.001). Similar proportions of POV and HOP patients had cancer-related surgery, radiation, and hormone therapy during the EOC period. In the multivariate analysis controlling for insurance type, age, and baseline comorbidity index score, number of infusions of trastuzumab per EOC remained lower in the HOP setting versus POV setting (Table 3 ; incident rate ratio [IRR] = 0.693, P < 0.001).
Health Care Resource Utilization. The event rate, incident rates, and length of inpatient stays are shown in Table 4 . Patients treated in the HOP setting had greater monthly utilization of outpatient visits and lesser monthly utilization of office visits compared with the POV cohort. The HOP cohort had a statistically significant higher rate of inpatient stays and lower rate of ER visits compared with the POV cohort (P < 0.001). The incident rate, defined as count of individuals experiencing at least 1 event over the follow-up period, was higher in the HOP cohort for inpatient stays (IRR = 1.263, P = 0.003). The mean duration of inpatient stays did not differ by setting.
Health Care
Costs. Unadjusted all-cause, cancer-related, and infusion day health care costs are shown in Table 5, and Table  3 illustrates the adjusted costs after controlling for insurance type, age, and baseline comorbidity score. Mean total overall costs were higher by $6,045 PPPM in the HOP versus POV settings ($17,304 vs. $11,259, P < 0.001). The major cost drivers were office visits in the POV setting ($8,453) and outpatient visits in the HOP ($15,665) setting, and the difference in total costs between cohorts was primarily driven by the difference in these costs. Mean total cancer-related costs were higher by $6,067 PPPM in the HOP setting (P < 0.001), and the difference in total costs was primarily a function of higher mean outpatient costs in the HOP setting ($15,268) compared with office costs ($8,319) in the POV setting. Mean actual infusion day costs were also higher in the HOP setting for both the broad ($6,748
higher per infusion day) and narrow ($6,352 higher per infusion day) definitions. In the multivariate analysis controlling for insurance type, age, and baseline comorbidity index score (Table 3) , HOP patients had 53.6% higher total monthly health care costs than POV patients (cost ratio = 1.536, P < 0.001). 
TABLE 2
Treatment Patterns for Adjuvant Patients Treated with Trastuzumab
infusions, patients managed in the HOP setting had 53.6% higher predicted total monthly health care costs than patients treated in the POV setting.
Cancer-related costs accounted for more than 90% of total actual monthly costs, and similar differences between site of service were evident. The costs per infusion day for patients treated in HOP clinics were approximately 2.7 times higher than costs for patients treated in POV settings and were the primary driver of higher cancer-related costs in the HOP setting. Privately commissioned studies have also noted higher costs for oncology patients receiving chemotherapy in HOP clinics. [13] [14] [15] During 2008-2010, commercially insured patients with the most common cancers incurred 34% higher total costs in the HOP setting per chemotherapy episode, and breast cancer patients had 11% higher costs per episode, 13 compared with patients treated in POV settings. There were several methodological differences between these studies and ours, including the treatment interval and regimens examined. Our study examined monthly costs for adjuvant treatment of nonmetastatic breast cancer only and over a longer intervalapproximately 11 months versus less than 4 months-and the earlier study noted that the cost difference for all cancer patients in the HOP versus POV settings rose to 30% to 77% for episodes lasting 9-12 months. 13 A separate analysis of Medicare fee-for-service patients identified 14% higher allowed costs for patients with common cancers receiving treatment in the HOP setting.
14 In a study of commercially insured patients with adjuvant treatment of breast cancer during 2009-2010, actual total costs per chemotherapy episode were approximately 50% higher in the HOP setting, 15 which is consistent with the 53.6% higher monthly costs that we observed for adjuvant treatment regimens that included trastuzumab.
We also observed significant differences in treatment pattern by site of service. The mean duration of the first episode
■■ Discussion
We examined treatment patterns, health care utilization, and costs by site of chemotherapy administration. To our knowledge, this is the first study to make this comparison for female breast cancer patients treated with adjuvant trastuzumab. Despite a shorter duration of treatment and fewer trastuzumab [20] [21] [22] [23] The first schedule is weekly for the first 12-18 weeks for combination chemotherapy regimens (2-4 milligrams per kilogram [mg/kg] depending on the regimen) and 6 mg/kg every 3 weeks thereafter. The second schedule is for use as a single agent every 3 weeks following anthracyline-based chemotherapy, starting at 8 mg/kg for the first administration and 6 mg/kg for the remainder. Although we were not able to capture the weight-based dose of trastuzumab administered, 67% of patients treated in HOP clinics had gaps in trastuzumab treatment of 30 days or more compared with 24% of patients in the POV setting.
Future studies should evaluate the impact of suboptimal treatment on patient outcomes and disease recurrence. Adverse events may also shorten treatment frequency and duration, and it is possible that patients treated in the HOP setting were recommended for treatment because their risk for clinical events that might require hospitalization was judged to be greater than patients treated in the POV setting. The choice of treatment setting may also be influenced by multiple factors, including the availability of services, patient preference, and other considerations that could not be evaluated in our study and warrant additional research.
With rising costs of cancer care, there is a need to identify opportunities to control treatment costs while maintaining or improving clinical outcomes. If a shift in chemotherapy administration from POV settings towards HOP clinics is occurring, as some have suggested, 11, 12 our results indicate that the shift would impose an additional cost burden for breast cancer patients treated with adjuvant trastuzumab. The Medicare Payment Advisory Commission has recently recommended delivery of care in the most cost-efficient setting after adjusting for differences in patient clinical severity. 24 Clinical outcome is the most important consideration for treatment of early stage breast cancer, and additional research is needed to evaluate any potential influence of site of service on survival. If outcomes are comparable between HOP and POV settings, our results suggest that POV settings provide more efficient delivery of care.
Limitations
Our results are based on claims data, and certain limitations apply. We used receipt of trastuzumab coupled with evidence of nonmetastatic breast cancer as a surrogate for adjuvant treatment of HER-2 breast cancer to minimize confounders such as breast cancer type and stage. However, it is possible that in our sample trastuzumab might have been used off-label for other types of breast cancer. Certain information is not readily available in claims data that could have had an effect on study outcomes, such as certain clinical and disease-specific parameters, which may result in residual confounding. For example, the reasons for selection of the treatment regimen and any of care was shorter in the HOP setting, and these results generally parallel previous reports. For commercially insured oncology patients, the mean duration of a chemotherapy episode was shorter in the HOP setting, 13 and Medicare fee-for-service cancer patients treated in the outpatient setting had fewer chemotherapy sessions per year.
14 In contrast, chemotherapy episodes were slightly longer for commercially insured patients with adjuvant treatment of breast cancer in the HOP setting compared with the POV setting (4.9 months vs. 4.7 months). 15 In the HOP setting, we also observed that patients were treated with fewer trastuzumab infusions per episode of care and per month, and a higher proportion of patients had gaps in treatment of 30 days or longer. The label for trastuzumab in adjuvant treatment of breast cancer indicates that patients should be administered a weight-based dose of trastuzumab for 52 weeks. There are 2 schedules for trastuzumab administration Patients at greater risk of adverse events may have been more likely to be treated in the HOP setting, and these patients may have also experienced a higher rate of adverse events during treatment, which would reduce treatment adherence rates in the HOP cohort. The reason for longer duration of treatment in the POV setting is also not apparent, nor was the study able to determine whether the difference in treatment duration may result in differing rates of recurrence, which requires longer follow-up periods. Differences in billing practices between hospital and physician office settings may have influenced our results for utilization of ER services. Hospitals may code ER services that result in admission as an inpatient service, and these events would not have been included in our calculation of ER utilization, potentially leading to the lower rates of ER utilization for patients treated in the HOP setting that we observed. Cancer patients may also be enrolled in clinical trials and may not have generated claims for some or all of the treatment received during the trial; our analysis would not include these data. Finally, our results are based on a managed care population and may not be applicable to patients with other forms of insurance or the uninsured.
■■ Conclusions
Our analysis suggests that patients who received adjuvant trastuzumab in HOP settings had fewer infusions of trastuzumab and higher health care costs than patients who received their therapy in POV settings. Additional studies are needed to confirm our findings, and these should include patient clinical characteristics that may influence site of care, reasons for nonadherence to treatment regimens, and factors that influence cost variation between the 2 settings. Studies employing a larger sample of patients stratified by geographic region and insurance type are also needed.
